Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
81 hedge funds and large institutions have $273M invested in Adamas Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 10 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 24
12% more capital invested
Capital invested by funds: $243M → $273M (+$29.5M)
4% less funds holding
Funds holding: 84 → 81 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $358K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BS
Bow Street
New York
|
+$10.1M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.48M |
| 3 |
Millennium Management
New York
|
+$2.44M |
| 4 |
BWCA
Brenner West Capital Advisors
New York
|
+$2.31M |
| 5 |
NC
Nexthera Capital
New York
|
+$1.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPH
C Partners Holding
Zurich,
Switzerland
|
-$8.78M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.47M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$1.51M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.05M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$943K |
ADMS Hedge Fund Activity: Q3 2016 in Review
81 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2016, worth a combined $273M — up 12% from $243M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ADMS and 7 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 27 added.
The largest buyer was Bow Street, adding an estimated $10.1M. The largest seller was C Partners Holding, cutting an estimated $8.78M.
- 81 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2016, down from 84 in Q2 2016.
- Funds reported $273M of Adamas Pharmaceuticals stock for Q3 2016, up 12% quarter-over-quarter.
- 7 funds opened new Adamas Pharmaceuticals positions in Q3 2016 and 10 closed out, a net change of -3 holders.
- The largest Adamas Pharmaceuticals buyer in Q3 2016 was Bow Street, an estimated $10.1M added.
- The largest Adamas Pharmaceuticals seller in Q3 2016 was C Partners Holding, an estimated $8.78M sold.
Based on aggregated 13F filings for Q3 2016.